Abstract
The tolerance of the vaginal mucosa to high dose rate brachytherapy (HDRB) has not been well described. This is especially important with the use of interstitial implants which are highly patient specific resulting in significant variations in vaginal mucosal dose between patients. Previously we reported on the differential dose to the distal and proximal ano-rectum with HDRB and here, we report on the correlation of vaginal mucosa dose to toxicity as well as quantify the differential tolerance between the proximal and distal vagina.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
